2 results for "Ervin".
#1354 Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome
Introduction: Telotristat etiprate (TE) reduces serotonin production. In TELESTAR, a phase 3 study in patients (pts) with carcinoid syndrome (CS) on somatostatin analogues with ≥4 bowel movements (BM) per day, TE significantly reduced BM frequency (freq). Overall (n=135), durable response (DR, ≥30% reduction in BMs/day for ≥50% of the study period) was observed in 44% (250 mg tid) and 42% (500 mg tid), vs 20% on placebo (PBO); p≤0.02 for each TE vs. PBO. A subset with similar demographics to the overall trial was interviewed.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#2229 The NETwork! Registry Suggests Increasing Incidence in a National Study of Neuroendocrine Cancer in New Zealand (NZ)
Introduction: NETwork! is a clinical and translational research program, including a retrospective epidemiological study of NETs in NZ.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Kate Parker